BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19936332)

  • 21. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?
    Strauss LG; Klippel S; Pan L; Schönleben K; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):868-77. PubMed ID: 17219134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
    Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study.
    Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Eisenhut M; Pan L; Haberkorn U; Strauss LG
    Mol Imaging Biol; 2007; 9(5):308-17. PubMed ID: 17623254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
    Spence AM; Muzi M; Mankoff DA; O'Sullivan SF; Link JM; Lewellen TK; Lewellen B; Pham P; Minoshima S; Swanson K; Krohn KA
    J Nucl Med; 2004 Oct; 45(10):1653-9. PubMed ID: 15471829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
    Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.
    Younis MH; Abu-Hijleh HA; Aldahamsheh OO; Abualruz A; Thalib L
    Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk assessment in liposarcoma patients based on FDG PET imaging.
    Brenner W; Eary JF; Hwang W; Vernon C; Conrad EU
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1290-5. PubMed ID: 16832631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.
    Li YJ; Dai YL; Cheng YS; Zhang WB; Tu CQ
    Eur J Surg Oncol; 2016 Aug; 42(8):1103-14. PubMed ID: 27189833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
    Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
    Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG.
    Dimitrakopoulou-Strauss A; Hohenberger P; Haberkorn U; Mäcke HR; Eisenhut M; Strauss LG
    J Nucl Med; 2007 Aug; 48(8):1245-50. PubMed ID: 17631559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.
    Lin C; Itti E; Haioun C; Petegnief Y; Luciani A; Dupuis J; Paone G; Talbot JN; Rahmouni A; Meignan M
    J Nucl Med; 2007 Oct; 48(10):1626-32. PubMed ID: 17873129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.
    Brenner W; Friedrich RE; Gawad KA; Hagel C; von Deimling A; de Wit M; Buchert R; Clausen M; Mautner VF
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):428-32. PubMed ID: 16404595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
    Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
    J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas.
    Been LB; Suurmeijer AJ; Elsinga PH; Jager PL; van Ginkel RJ; Hoekstra HJ
    J Nucl Med; 2007 Mar; 48(3):367-72. PubMed ID: 17332613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
    Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
    J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.
    Schwarzbach MH; Hinz U; Dimitrakopoulou-Strauss A; Willeke F; Cardona S; Mechtersheimer G; Lehnert T; Strauss LG; Herfarth C; Büchler MW
    Ann Surg; 2005 Feb; 241(2):286-94. PubMed ID: 15650639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.